Commitments and Contingent Liabilities (Details) $ / shares in Units, ₪ in Thousands, $ in Thousands |
1 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2015
USD ($)
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
Dec. 31, 2017
USD ($)
$ / shares
|
Dec. 31, 2017
ILS (₪)
|
Dec. 31, 2016
USD ($)
|
Dec. 31, 2019
ILS (₪)
|
May 31, 2017
shares
|
|
| Commitments and Contingent Liabilities (Textual) | ||||||||
| Approved budget | $ 781 | |||||||
| Percentage of approved budget | 30.00% | 85.00% | 85.00% | |||||
| Amount of deduction from R&D expense | $ 299 | $ 646 | ||||||
| Contingent obligation | 2,300 | |||||||
| New application of total budget amount | $ 3,100 | |||||||
| Other Commitments, description | The program is for the period beginning from July 2019 through December 2019. | |||||||
| Additional budget | $ 11,900 | |||||||
| Annual license fees | $ 10 | |||||||
| License fees, description | Annual license fees of between $15 thousand to $25 thousand subject to the terms and conditions specified in the agreement. | Annual license fees of between $15 thousand to $25 thousand subject to the terms and conditions specified in the agreement. | ||||||
| Royalty payments based on future revenue | $ 3,200 | |||||||
| Amount of liabilites recorded to agrement | 217 | |||||||
| 2017 License Agreement [Member] | ||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||
| Annual license fees | $ 10 | 10 | $ 10 | |||||
| Warrants to purchase ordinary shares | shares | 591,382 | |||||||
| Nominal value | $ / shares | $ 0.0001 | |||||||
| Additional Lease Agreements [Member] | ||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||
| Commitments and Contingent Liabilities, description | (i) to pay a license issue fee of $20 thousand and annual license fees ranging from $15 thousand to $25 thousand; (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million (“milestone payments”); and (iii) make tiered royalty payments, in the low single digits based on future revenue. | |||||||
| License and Maintenance [Member] | ||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||
| Other Commitments, description | BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate, as well as royalty payments on future revenues. The consolidated financial statements include a liability with respect to this agreement in the amount of $108 thousand as of December 31, 2019. There was no liability recorded with respect to this agreement as of December 31, 2018. | BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate, as well as royalty payments on future revenues. The consolidated financial statements include a liability with respect to this agreement in the amount of $108 thousand as of December 31, 2019. There was no liability recorded with respect to this agreement as of December 31, 2018. | ||||||
| Annual license fees | $ 25 | $ 25 | $ 25 | |||||
| Maximum payments of license maintenance fees | 250 | |||||||
| License Agreement [Member] | ||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||
| Approved budget | $ 1,800 | |||||||
| Annual license fees | $ 10 | |||||||
| Maximum [Member] | ||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||
| Royalties rate | 3.00% | 3.00% | ||||||
| Minimum [Member] | ||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||
| Royalties rate | 3.50% | 3.50% | ||||||
| NIS [Member] | ||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||
| Approved budget | ₪ | ₪ 2,700 | |||||||
| New application of total budget amount | $ 10,800 | |||||||
| Additional budget | ₪ | ₪ 41,400 | |||||||